PURPOSE: Cheyne-Stokes respiration (CSR) is a known controversial prognostic marker in patients with heart failure (HF). Little is known, moreover, about the development and progress of CSR in such patients. The CSR progress over time may be indicative for clinical deterioration in patients with HF disease METHODS: Prospective cohort sleep studies, with algorithm-based analyses of continuously or periodically monitored changes over time using standard pulse oximeter. Home testing for 4 months of patients recruited from the cardiology department of a large community medical center in Haifa, Israel. A total of 36 patients, 31 men and five women, aged between 50 and 74 years, with symptomatic chronic HF. RESULTS: Out of the 36 patients, 15 (42%) patients were found to have CSR. The CSR cycle length was chosen as the characteristic parameter which determines the periodicity of the event and its length. Analyses of CSR cycle length and duration in the 15 patients showed changes over time in the length of the CSR event only in patient with New York Heart Association (NYHA) 4 classification. CONCLUSIONS: Nocturnal CSR in patients with HF show small variations over time in the prevalence or duration of the cycle length and could be a marker for entering stage 4 or deterioration in the NYHA class of HF patient. Moreover, it may take years for HF patients to develop CSR or to increase the length of the cycle length of existing CSR, if they develop it at all.
PURPOSE: Cheyne-Stokes respiration (CSR) is a known controversial prognostic marker in patients with heart failure (HF). Little is known, moreover, about the development and progress of CSR in such patients. The CSR progress over time may be indicative for clinical deterioration in patients with HF disease METHODS: Prospective cohort sleep studies, with algorithm-based analyses of continuously or periodically monitored changes over time using standard pulse oximeter. Home testing for 4 months of patients recruited from the cardiology department of a large community medical center in Haifa, Israel. A total of 36 patients, 31 men and five women, aged between 50 and 74 years, with symptomatic chronic HF. RESULTS: Out of the 36 patients, 15 (42%) patients were found to have CSR. The CSR cycle length was chosen as the characteristic parameter which determines the periodicity of the event and its length. Analyses of CSR cycle length and duration in the 15 patients showed changes over time in the length of the CSR event only in patient with New York Heart Association (NYHA) 4 classification. CONCLUSIONS: Nocturnal CSR in patients with HF show small variations over time in the prevalence or duration of the cycle length and could be a marker for entering stage 4 or deterioration in the NYHA class of HF patient. Moreover, it may take years for HF patients to develop CSR or to increase the length of the cycle length of existing CSR, if they develop it at all.
Authors: P Ponikowski; S D Anker; T P Chua; D Francis; W Banasiak; P A Poole-Wilson; A J Coats; M Piepoli Journal: Circulation Date: 1999-12-14 Impact factor: 29.690
Authors: P A Lanfranchi; A Braghiroli; E Bosimini; G Mazzuero; R Colombo; C F Donner; P Giannuzzi Journal: Circulation Date: 1999-03-23 Impact factor: 29.690
Authors: Offer Amir; Deganit Barak-Shinar; Yariv Amos; Mary MacDonald; Stephen Pittman; David P White Journal: J Clin Sleep Med Date: 2010-02-15 Impact factor: 4.062
Authors: S Javaheri; T J Parker; J D Liming; W S Corbett; H Nishiyama; L Wexler; G A Roselle Journal: Circulation Date: 1998-06-02 Impact factor: 29.690
Authors: Maria Teresa La Rovere; Gian Domenico Pinna; Roberto Maestri; Elena Robbi; Andrea Mortara; Francesco Fanfulla; Oreste Febo; Peter Sleight Journal: Eur J Heart Fail Date: 2007-07-26 Impact factor: 15.534
Authors: Andrew L Clark; Christoph Knosalla; Emma Birks; Matthias Loebe; Constantinos H Davos; Sui Tsang; Abdissa Negassa; Magdi Yacoub; Roland Hetzer; Andrew J S Coats; Stefan D Anker Journal: Eur J Heart Fail Date: 2007-05-29 Impact factor: 15.534